The Mesothelioma Applied Research Foundation has announced the recipients of its 2009 Mesothelioma Research Grant Awards. Through the generous contributions of its supporters, the Foundation was able to fund eight promising research projects. Executive Director Christopher E. Hahn reports that this is 60 percent more than the organization funded in 2008, when the Foundation, along with many charitable endeavors were beset by budget cuts resulting from the tough economic climate. In an email to Meso Foundation supporters, Hahn said he is hopeful the organization will soon be able to return to its target goal of funding 10 mesothelioma research projects per year.
Projects funded by the 2009 Grant Awards include vaccine studies offering hope of targeted treatment without drastic side effects; a novel investigation of the role of hormones in mesothelioma treatment; developing pathway targets synergistic with current first-line therapy Alimta/Cisplatin; and a study specifically focusing on improved detection and treatment of peritoneal mesothelioma (affecting the lining of the abdomen). Visit the Meso Foundation online for details of each study.
Each year, the Mesothelioma Applied Research Foundation funds critically needed research to develop more effective treatments and ultimately, a cure. The Foundation has provided more than $6 million in grant funding, advancing mesothelioma science through promising studies around the world. The Meso Foundation’s funding objectives are to directly fund basic research and support clinical trials in worthy, peer-reviewed projects as well as to stimulate additional federal research funding opportunities.
The Mesothelioma Applied Research Foundation is a nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma.
You can help! There are many ways to get involved with the Mesothelioma Applied Research Foundation. These include signing up to receive and respond to Action Alerts, which are specific campaigns for particular aspects of mesothelioma advocacy efforts; visiting your government officials to lobby for mesothelioma funding and awareness; volunteering in the meso community both locally and nationally; education; sharing your meso story; and donating to mesothelioma research.
For more information or to make a donation, visit the How You Can Help page at www.curemeso.org. The Meso Foundation is the recipient of the Charity Navigator “Four Star Charity” award and is recognized as the 2009 Great Nonprofits winner in the category of Cancer Fighters.
A recent report on WDIO-DT and WIRT-DT ABC stations 10 and 13 says approximately 1,000 Iron Range miners and their families have been screened as part of an ongoing study into the link between taconite mining and mesothelioma. The study is being directed by the University of Minnesota and the Minnesota Department of Health, and funded by the Minnesota State Legislature, which allocated $4.9 million to the project in April 2008.
An investigation into the link between taconite mining – which takes place in what is known as Minnesota’s Iron Range – began when state health officials noted an unusually high incidence of mesothelioma occurring in taconite mine workers. Mesothelioma is traditionally linked only to asbestos exposure. There is a theory that the taconite mineral may contain similar fibers to asbestos mineral.
Researchers began screening workers and their immediate family members in July. According to the news report, researchers say the study is on track. They would like to see about another 1,000 people, however. Analysis of the respiratory is estimated to take another 18 months.
This screening is one part of the comprehensive five-year study. There are four health studies associated with the project, including a mortality study under the direction of the Minnesota Department of Health and related to miner deaths; a cancer rate incidence study; a respiratory health assessment for miners or former miners (and expanded to include spouses or other close family that may have had secondary exposure to taconite dust), and an occupational exposure study.
On Dec. 31, the online celebrity news source, TMZ, revealed that football and television star Merlin Olsen has filed a lawsuit against a number of companies, claiming they are responsible for exposing him to asbestos, resulting in his recent diagnosis of malignant mesothelioma. Companies named in the suit are Sherwin Williams and Lennox Industries, whose products Olsen says he was exposed to during jobs in his youth, but also NBC Studios, NBC Universal, and 20th Century Fox Film Corporation. It is unclear from the lawsuit how the television and movie companies contributed to Olsen’s asbestos exposure.
Olsen was a professional football player for the Los Angeles Rams team, and later had a successful career as a sportscaster and actor, most notably on shows “Little House on the Prairie” and “Father Murphy.”
According to the lawsuit, filed in Los Angeles County Superior Court, the defendants “were engaged in the business of manufacturing, fabricating, designing, assembling, distributing, leasing, buying, selling, inspecting, servicing, installing, repairing, marketing, warranting and advertising a certain substance the generic name of which is asbestos.”
News reports say Olsen, with wife Susan by his side, is fighting his mesothelioma and currently undergoing chemotherapy.
A December report by the New York Times revealed that Sen. Max Baucus (D-Montana) has inserted language into the government’s proposed health care legislation that would provide coverage specifically for people exposed to asbestos in Libby, Montana. According to the report, language in the bill would expand Medicare coverage to vicitims of “environmental health hazards.”
According to the Times, the language is even more precise, calling for coverage for “individuals exposed to environmental health hazards recognized as a public health emergency in a declaration issued by the fedearl government on June 17.” This declaration and date, of course, coincides with the U.S. Environmental Protection Agency’s designation of Libby as a Public Health Emergency area.
The Times quotes Baucus as saying the language is not only intended for the people of Libby, but for anyone in the future whose town is affected by a similar tragedy that affects the health and well-being of its people. He said the legislation would provide a safety net to “help people when they need it most.”
Both the U.S. House of Representatives and the U.S. Senate passed their versions of the health care reform bill last year. It is now up to the 111th Congress as a whole to reconcile the two bills so that they may be presented to President Obama for his signature.
Congressional leaders say they hope to accomplish this by the end of January.
If you are a fan of the social networking site Facebook, I hope that you are linked into the many mesothelioma survivors, supporters, groups and victims that are posting regularly there. If you don’t already have a Facebook page, setting one up is easy. Just go to www.facebook.com and the easy instructions on the home page will walk you through the steps. There are lots of new and improved privacy controls that you can set so that you don’t have to share more information than you want to. The nice thing about Facebook is that you accept and approve “friends” who can see your information.
Our good friend Debbie Brewer in the UK is online on Facebook. Just search for her name and you’ll come to her profile. She recently has started a Facebook fan page for Dr. Thomas Vogl, the groundbreaking researcher who is pioneering chemoembolization as a treatment for mesothelioma. Those familiar with Debbie’s story know that she has had great success with chemoembolization under Dr. Vogl’s care. You can visit his page here: http://tinyurl.com/yeq5969
There also is a group set up to honor Debbie herself! You can find it by clicking this link: http://tinyurl.com/ychey9g
There is a special event planned for this Friday, Jan. 15, to celebrate Debbie, as well. “Raise a Glass to Debbie” asks everyone to raise a toast in honor of Debbie’s work as an activist for mesothelioma awareness and the fight for a cure. The event will occur between 8 p.m. and 11 p.m. and it doesn’t matter where in the world you are – the UK, the U.S., Australia, or any point on the globe – just join in!
There are so many wonderful support groups on Facebook. Two of these that my regular readers know I talk about a lot are the Asbestos Disease Awareness Organization (ADAO) (find them here: http://tinyurl.com/ybhmn9j) and the Mesothelioma Applied Research Foundation (http://tinyurl.com/ybv2uut).
Princeton University announced Edward Taylor, its A. Barton Hepburn Professor of Organic Chemistry Emeritus, will be inducted into the American Chemical Society (ACS) Division of Medicinal Chemistry Hall of Fame in 2010. Additionally, Taylor has been inducted into the New Jersey Inventors Hall of Fame and was selected to receive the 2010 Alfred Burger Award in Medicinal Chemistry from the ACS. Taylor was instrumental in the development of Alimta, a drug manufactured by Eli Lilly and Co. and approved for the treatment of malignant pleural mesothelioma by the U.S. Food & Drug Administration in 2004.
Taylor was recently honored for his accomplishments at the Celebrate Princeton Invention reception, held Dec. 18. He developed Alimta in partnership with scientists at Eli Lilly and Co. after spending more than 40 years on the Princeton faculty. However, he began research that would lead to the mesothelioma drug’s development while a graduate student at Cornell University.
According to a Princeton news release, Taylor became fascinated by reports of a compound obtained from spinach and liver that had a unique chemical structure with a nucleus previously only observed in the pigments of butterfly wings. The compound from liver, now known as folic acid, he found was essential for the synthesis of DNA and RNA, and for the growth of cells. Taylor observed that changes to the structure of folic acid could transform it from a growth-promoting to a growth-inhibiting compound, and dedicated his career to determine how it could be used to kill cancer cells.
Since its approval by the FDA in 2004, the drug has received three additional FDA approvals, most recently in July when it became the first chemotherapy approved for use as a maintenance therapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. Alimta has been successful in improving the quality of life and extending the lifespan of millions of cancer patients in nearly 100 countries around the world.
Taylor has previously been honored with the ACS Heroes of Chemistry Award, the International Society of Heterocyclic Chemistry Senior Award in Heterocyclic Chemistry, and the Research and Development Council of New Jersey’s Thomas Alva Edison Patent Award for Invention.
It has been a difficult year for many in the mesothelioma family. Many have lost loved ones, or are facing a scary diagnosis. But 2009 also held a lot of good news. To illustrate that, I’d like to share a news article about our great friend in the UK, Debbie Brewer. Just after Christmas, Debbie was featured on the front page of The Herald, a newspaper that covers the Plymouth area. The paper describes Plymouth as a “hotspot for asbestos-related deaths.”
In the feature, Debbie talks about how she moved from what was presented to her as a death sentence to her new outlook of happiness, hope and survival. Debbie was diagnosed in November 2006, at which time she thought she might be seeing her last Christmas. Doctors estimated she had only six to nine months to live.
As most of you know, Debbie refused to accept the prognosis that she had only months to live, instead actively seeking alternative medical treatments that might take a fresh look at her cancer and provide her with new options. Primarily, she found Prof. Thomas Vogl at the University Clinic in Frankfurt, Germany, who administers a therapy called chemoembolization. In this therapy, chemotherapy drugs are introduced directly to the tumor area through a catheter into the lung.
Because the treatment is still in clinical trial stages, Debbie had to travel to Germany for each treatment, not available in the UK, and paid for travel expenses and medical care from her own pocket. However, results were amazing, and Debbie’s tumor shrunk by more than 80 percent, putting her in full remission.
Despite a recent setback, when a September check-up showed cancer in her lymph node had increased in size (the tumor in her lung remains stable), she is optimistic. She lobbies energetically for mesothelioma and asbestos awareness, and also to bring chemoembolization to the UK so that more people might try this new therapy that has shown so much success in her case.
The paper quotes Debbie as saying, “Christmas is the time of year I celebrate being here. ”
We love you, Debbie, and we are SO glad to celebrate another Christmas with you, and we look forward to spending 2010 with you!
As part of its look back at the year 2009, the Missioulian newspaper spoke with residents of Libby, Montana, the “poster child” for mesothelioma and other asbestos related diseases. Libby and its people have been decimated by asbestos exposure from the vermiculite mine that for generations operated in the town. Even those who did not work in the mine were affected, as asbestos dust blanketed the town, spilled from trucks and railway cars, and asbestos particles were used as landfill throughout the town.
W.R. Grace & Company operated the mine. In 2009, the company and several of its officers were brought up on criminal charges, but a jury returned a verdict of “not guilty.” Many following the trial closely said the government botched its case against the company, and others argued Grace’s deep pockets simply outpaced the efforts of a handful of government lawyers.
The aquittal was another in a long line of emotional blows for Libby residents, who hoped to see W.R. Grace finally brought to justice for the devastation of their hometown, their families and loved ones. Generations of Libby residents have already died of mesothelioma, and many more are currently suffering from mesothelioma, asbestosis, lung cancer, and a host of other ailments caused by longterm exposure to asbestos.
On June 17, the U.S. Environmental Protection Agency finally declared a public health emergency in Libby. This designation – the first of its kind in American history – will allow the government to increase funds to provide for medical treatment for Libby residents, and for research into asbestos disease. According to the Missoulian, Libby has already received $6 million, which is designated for patient screening and care, and the town is set to receive an additional $2 million for health care and home care assistance. The paper reports the asbestos health care clinic – the Center for Asbestos Related Diseases (CARD) – and the local hospital are planning expansions.
At the beginning of December, a series of town hall meetings were held, hoping to address important questions about safety and health, including whether or not the government’s clean-up efforts are truly making any difference.
For residents who already have seen husbands, fathers, brothers, sisters, husbands and wives die terrible deaths from asbestos disease, it is too little too late. They try to remain strong, but they are angry, and sad, and it’s hard to hold onto hope.
As 2009 draws to a close, the Mesothelioma Applied Research Foundation would like to remind those of us in the meso community that there is still much work to be done in the quest for a cure. The Meso Foundation has created a powerful two-minute video featuring the testimonies of mesothelioma victims and their families, including heartbreaking stories of loss, but also triumphant declarations of success against this dreaded cancer.
Please share the following video with your family and friends, and fellow mesothelioma warriors, and help raise awareness about the many lives touched by mesothelioma.
You can visit the Meso Foundation online to make a donation to help this organization fund mesothelioma reserach and continue providing patient services, or mail your contribution to:
Mesothelioma Applied Research Foundation
P.O. Box 91840
Santa Barbara, CA 93190-1840
You may specify a loved one in whose memory the contribution is made, which will be acknowledged on the Tribute Wall, displayed at the annual International Symposium on Malignant Mesothelioma in June 2010. Contributions over $100 also will be acknowledged in the Meso Foundation Annual Report. There is much more information online about how you can help. Please visit them today!
On Monday, December 28, the Asbestos Disease Awareness Organization (ADAO) will continue a longstanding tradition of lighting a candle in memory of those loved ones lost to mesothelioma. This is actually the first of two candlelighting ceremonies. The second will be held Monday, January 4, 2010, in honor of all the mesothelioma “warriors” still battling and conquering this devastating disease.
You are invited to add the name of your loved one to ADAO’s master list, either in memory or in honor of someone you love. This project is conducted in conjunction with the Association of Cancer Online Resources (ACOR). View the list, or email acor@AsbestosDiseaseAwareness.org to add a name to the list.
Linda Reinstein, ADAO’s co-founder, says, “Since founding ADAO in March 2004, thanks to the efforts for our all-volunteer organization, we have grown beyond our initial expectations. Our passion and commitment to preventing asbestos exposure, offering support and resources and remaining unwaveringly committed to banning asbestos and funding research for a cure has gained momentum and recognition on The Hill. You have been heard! Thank you for your continued support of ADAO, ‘the voice of the victims,’ as together, change is possible.”
Please join the mesothelioma community on Monday and light your candle in memory of those whose battle has sadly ended, and make plans to celebrate the life of a meso warrior on January 4.
The Mesothelioma Applied Research Foundation has announced the recipients of its 2009 Mesothelioma Research Grant Awards. Through the generous contributions of its supporters, the Foundation was able to fund eight promising research projects. Executive Director Christopher E. Hahn reports that this is 60 percent more than the organization funded in 2008, when the Foundation, along with many charitable endeavors were beset by budget cuts resulting from the tough economic climate. In an email to Meso Foundation supporters, Hahn said he is hopeful the organization will soon be able to return to its target goal of funding 10 mesothelioma research projects per year.
